Hellion (NYSE:HLN) is one of them Most pledge deposits under $20. On February 25, Helon reported financial performance for the full year 2025, marked by the introduction of its ‘Win as One’ strategy and 3% organic revenue growth. While results in North America were tempered by low consumer confidence and weak cold and flu weather, the company saw strong growth in its EMEA, Latin America, and Asia-Pacific regions.
Total revenue reached £11.03 billion, supported by the Oral Health sector, which performed well with ~8% organic growth. These results allowed the company to maintain or gain market share in 60% of its business segment. Profitability was driven by productive manufacturing innovations including a 26% reduction in SKU complexity and optimized logistics. Despite market challenges, the company continued to reinvest in its future, increasing R&D spending by 7.7%.
For 2026, Hellion (NYSE:HLN) expects organic revenue growth to accelerate between 3% and 5%, supported by a new operating model designed to increase agility. The company created the role of chief growth officer and organized it into six distinct operating units to optimize regional opportunities. Management plans to deliver high single-digit adjusted operating profit growth and set aside £500 million for share buybacks next year.
Haleon (NYSE:HLN), together with its subsidiaries, researches, develops, manufactures, and sells various consumer health products in North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific.
While we acknowledge HLN’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 40 most popular stocks among hedge funds heading into 2026 and 33 stocks that should double in 3 years.
Disclosure: None. Follow the inside port on Google News.
